Literature DB >> 2013980

Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.

F Mertens1, B Johansson, S Heim, U Kristoffersson, F Mitelman.   

Abstract

During the 15 year period 1975-1989, 74 cases of chronic myeloproliferative disorder (CMPD) were cytogenetically analyzed in our department. Thirty patients had polycythemia vera (PV), 23 had idiopathic myelofibrosis (MFS), 15 had idiopathic thrombocythemia (IT), and six had unclassifiable CMPD (UCMPD). The overall frequency of clonal chromosome aberrations was 36% (50% in PV, 30% in MFS, 27% in IT, and 17% in UCMPD). The frequency was markedly higher (53%) in the subset of patients who had received myelosuppressive therapy and/or had developed acute leukemia prior to the initial cytogenetic analysis. The pattern of the chromosome rearrangements in our series is in agreement with the karyotypic findings in the 411 previously reported cases of CMPD. Trisomy 8 and 9 and del(20q) dominate in PV. The picture in MFS is more heterogenous with several aberrations, dup(1q), -5, del(5q), -7, del(7q), +8, +9, del(13q), del(20q), and +21, found equally frequently. No pathognomonic chromosome aberration has been detected in IT, but t(9;22) occurs more often than other changes. Thus, although a non-random cytogenetic pattern is discernible in CMPD, there is considerable overlap both with other myeloid malignancies and among the different CMPD subtypes.

Entities:  

Mesh:

Year:  1991        PMID: 2013980

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

2.  Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality.

Authors:  Noelle V Frey; Christopher E Leid; Peter C Nowell; Ewa Tomczak; Honore T Strauser; Margaret Kasner; Steven Goldstein; Alison Loren; Edward Stadtmauer; Selina Luger; Elizabeth Hexner; Joanne Hinkle; David L Porter
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

3.  Immunophenotypic characterisation of acute leukaemia after polycythemia vera.

Authors:  J M Hernández; A Orfao; M González; B Cuesta; M C López-Berges; M C Cañizo; J Ciudad; J F San Miguel
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

4.  Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.

Authors:  Philip A Beer; Peter J Campbell; Anthony R Green
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

5.  Cytogenetics findings in a histiocytic sarcoma case.

Authors:  J M Alonso-Dominguez; M Calbacho; M Talavera; C Villalon; L Abalo; J V Garcia-Gutierrez; S Lozano; M Tenorio; J Villarrubia; J Lopez-Jimenez; M T Ferro
Journal:  Case Rep Hematol       Date:  2012-06-03

Review 6.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

7.  Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.

Authors:  C D DiNardo; N Daver; N Jain; N Pemmaraju; C Bueso-Ramos; C C Yin; S Pierce; E Jabbour; J E Cortes; H M Kantarjian; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.